Strategic Acquisition NantPharma has a history of strategic acquisitions and partnerships, including the Cynviloq development rights and the Abraxane acquisition by NantPharma. This suggests opportunities to position their injectable pharma capabilities as a partner for late-stage oncology assets or high-value biologics needing specialized manufacturing and development support.

Oncology Focus With experience in oncology drug development and the legacy of Cynviloq and Abraxane-related programs, target collaborations around next-generation cancer therapies, including RNA-based approaches, that can leverage NantPharma’s US-based manufacturing and R&D presence.

Manufacturing Footprint NantPharma operates a US-based manufacturing facility and an R&D lab, plus a focus on injectable products. This combination supports opportunities to co-develop and manufacture complex injectables or biosimilars for US and European markets, appealing to companies seeking nearshore or onshore manufacturing options.

Regulatory & Quality The emphasis on high-quality, fully integrated platforms signals readiness to handle regulated manufacturing for injectable therapeutics. Use this to pitch end-to-end solutions covering development, scale-up, and compliant manufacturing for experienced pharma brands expanding into US markets.

Growth & Funding Signals Past financial activities and Blackstone backing indicate capacity for scaling partnerships and potential co-development agreements. Approach opportunities with a value proposition around rapid expansion, risk-sharing, and access to capital for joint development programs.